- Home
- LAC vs PRME Comparison
LAC vs PRME Comparison
Compare LAC & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAC
- PRME
- Stock Information
- Founded
- LAC 2023
- PRME 2019
- Country
- LAC Canada
- PRME United States
- Employees
- LAC N/A
- PRME N/A
- Industry
- LAC Metal Mining
- PRME Medicinal Chemicals and Botanical Products
- Sector
- LAC Basic Materials
- PRME Health Care
- Exchange
- LAC Nasdaq
- PRME Nasdaq
- Market Cap
- LAC 722.6M
- PRME 693.5M
- IPO Year
- LAC N/A
- PRME 2022
- Fundamental
- Price
- LAC $5.86
- PRME $4.72
- Analyst Decision
- LAC Hold
- PRME Buy
- Analyst Count
- LAC 8
- PRME 6
- Target Price
- LAC $5.44
- PRME $8.88
- AVG Volume (30 Days)
- LAC 75.4M
- PRME 4.2M
- Earning Date
- LAC 11-07-2025
- PRME 11-07-2025
- Dividend Yield
- LAC N/A
- PRME N/A
- EPS Growth
- LAC N/A
- PRME N/A
- EPS
- LAC N/A
- PRME N/A
- Revenue
- LAC N/A
- PRME $4,961,000.00
- Revenue This Year
- LAC N/A
- PRME $179.58
- Revenue Next Year
- LAC N/A
- PRME N/A
- P/E Ratio
- LAC N/A
- PRME N/A
- Revenue Growth
- LAC N/A
- PRME 739.42
- 52 Week Low
- LAC $2.31
- PRME $1.11
- 52 Week High
- LAC $10.52
- PRME $6.94
- Technical
- Relative Strength Index (RSI)
- LAC 45.05
- PRME 42.71
- Support Level
- LAC $5.72
- PRME $4.93
- Resistance Level
- LAC $7.00
- PRME $5.55
- Average True Range (ATR)
- LAC 0.82
- PRME 0.56
- MACD
- LAC -0.41
- PRME -0.20
- Stochastic Oscillator
- LAC 2.11
- PRME 2.98
About LAC Lithium Americas Corp.
Lithium Americas is a pure-play lithium producer. The firm owns 62% of one resource, Thacker Pass, which is located in northwest Nevada, with automaker General Motors owning the remaining 38%. Thacker Pass is under construction and expected to begin production in 2028. Thacker Pass is one of the largest known lithium resources in the world. The project would be the first clay-based asset to enter production, and we estimate it will be in bottom half of the global cost curve. Management plans to develop Thacker Pass into a fully integrated lithium production site, with downstream refining capabilities on site, and will sell into the lithium chemical market.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.